Unilateral retinoblastoma: new intraocular tumours after treatment.

Abramson, David H.; Gamell, Lisa; Ellsworth, Robert M.; Kruger, Erik; Servodidio, Camille A.; Turner, Liebert; Sussman, David M.

doi:10.1136/bjo.78.9.698

Cited by 37 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are in keeping with those reported by Abramson et al 18 and Wilson et al ,19 who found family history and young age of presentation to be associated with increased risk of developing new tumours. Interestingly, eight (15%) of the unilateral patients in the present study (not including the abovementioned one) were found to be genetic cases; however, these too remained unilateral throughout follow-up.…”

Section: Discussionsupporting

confidence: 93%

Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In developing countries, where family incomes are modest and access to care is limited, early enucleation for advanced intraocular unilateral retinoblastoma is to be recommended. However, a case for eye preservation can be made for patients who present with unilateral retinoblastoma before 6 months of age, because the possibility of asynchronous retinoblastoma is a significant concern [12].…”

Section: Discussionmentioning

confidence: 99%

Enucleation for retinoblastoma: the experience of a single center in Jordan

et al. 2010

View full text Add to dashboard Cite

Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93%) had advanced disease (RE groups IV and V). Seventeen patients (61%) had unilateral retinoblastoma, and 11 (39%) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71%) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated at the time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47%) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.

show abstract

“…About 4% of children with an initial diagnosis of unilateral retinoblastoma develop new intraocular tumour foci in the other eye (metachronous bilateral tumours) after treatment 2. To assure early detection and treatment of the few patients who develop new tumour foci, repeated follow-up eye examinations under anaesthesia are recommended for all patients with unilateral retinoblastoma until 5 years of age.…”

Section: Introductionmentioning

confidence: 99%

“…To assure early detection and treatment of the few patients who develop new tumour foci, repeated follow-up eye examinations under anaesthesia are recommended for all patients with unilateral retinoblastoma until 5 years of age. Studies undertaken to this end so far have shown that early age at initial diagnosis and initial diagnosis of multifocal tumours are associated with a higher than average risk 2 3. The strongest risk factor for development of metachronous bilateral tumours is a positive family history of retinoblastoma.…”

Section: Introductionmentioning

confidence: 99%

Sporadic unilateral retinoblastoma or first sign of bilateral disease?

et al. 2013

View full text Add to dashboard Cite

This study shows that an oncogenic RB1 mutation in the blood is a risk factor for metachronous bilateral retinoblastoma. Additional clinical risk factors for metachronous bilateral disease are diagnosis at young age (≤0.5 years) and multifocal unilateral retinoblastoma. Early genetic analysis may identify children at high risk of developing metachronous bilateral disease and may help to preserve vision using risk-adapted follow-up and early treatment.

show abstract

Unilateral retinoblastoma: new intraocular tumours after treatment.

Abstract: (Br3r Ophthalmol 1994; 78: 698-701)

Cited by 37 publications

References 12 publications

Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye

Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye

Enucleation for retinoblastoma: the experience of a single center in Jordan

Sporadic unilateral retinoblastoma or first sign of bilateral disease?

Contact Info

Product

Resources

About